The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 16, 2017

Filed:

Oct. 15, 2012
Applicants:

The United States of America, As Represented BY the Secretary, Department of Health and Human Service, Washington, DC (US);

Cooper Health System, Camden, NJ (US);

Sri International, Menlo Park, CA (US);

Inventors:

Irving W. Wainer, Washington, DC (US);

Ruin Moaddel, Bel Air, MD (US);

Michel Bernier, Pikesville, MD (US);

Carlos A. Zarate, Germantown, MD (US);

Marc C. Torjman, Southampton, PA (US);

Michael E. Goldberg, Philadelphia, PA (US);

Mary J. Tanga, Los Altos, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 295/155 (2006.01); C07C 225/20 (2006.01); C07C 237/04 (2006.01); C07D 295/108 (2006.01); C07D 295/112 (2006.01); C07C 229/48 (2006.01); C07C 237/20 (2006.01); C07D 295/15 (2006.01);
U.S. Cl.
CPC ...
C07D 295/155 (2013.01); C07C 225/20 (2013.01); C07C 229/48 (2013.01); C07C 237/04 (2013.01); C07C 237/20 (2013.01); C07D 295/108 (2013.01); C07D 295/112 (2013.01); C07D 295/15 (2013.01); C07B 2200/07 (2013.01); C07C 2101/14 (2013.01); C07C 2101/16 (2013.01);
Abstract

The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.


Find Patent Forward Citations

Loading…